13FGuru
Sign in with Google Sign in with Discord

NASDAQ · Health Care

ILLUMINA INC ILMN

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Sources StockAnalysis company profile stockanalysis.com
Medical Specialities

Company profile

Business mix

  • The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation.
  • It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services.
  • The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.
  • The company markets and distributes its products directly to customers, as well as through life-science distributors.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within diagnostics & research?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 5 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE 29.42 FCF 3.97% Buyback 2.67%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Corvex Management Keith Meister 18.8% $472.0M 2026-03-31
Sessa Capital 7.3% $403.8M 2026-03-31
Baillie Gifford legacy James Anderson 0.2% $189.2M 2026-03-31
Gotham Asset Management Joel Greenblatt 0.1% $42.1M 2026-03-31
Triple Frond Partners 3.9% $37.8M 2026-03-31

Recent trading changes over the last 4 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 3 Last 4 13F filing periods
Net reducers 1 Last 4 13F filing periods
Unchanged holders 4 Share count unchanged
Increase amount $465.4M Estimated from net added shares
Reduction amount $181.9M Estimated from net reduced shares
Net share change / base shares +32.9% +2,300,346 / 6,988,613
Gotham Asset Management Joel Greenblatt 3 filing periods
13F 2025-09-30 Filed 2025-11-14
Major increase Shares 97.5% 13F value change +$13.7M
13F 2025-12-31 Filed 2026-02-17
Minor increase Shares 7.6% 13F value change +$13.5M
13F 2026-03-31 Filed 2026-05-15
Minor increase Shares 8.5% 13F value change +$830,582
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 148,213 Last 4 periods +193,723 (+130.7%) Total shares 341,936 Value $42.1M
Triple Frond Partners 3 filing periods
13F 2025-09-30 Filed 2025-11-14
New Shares - 13F value change +$37.1M
13F 2025-12-31 Filed 2026-02-13
Minor reduction Shares -4.2% 13F value change +$12.0M
13F 2026-03-31 Filed 2026-05-15
Major reduction Shares -18.1% 13F value change -$11.3M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 0 Last 4 periods +306,460 (New) Total shares 306,460 Value $37.8M
Corvex Management Keith Meister 4 filing periods
13F 2025-06-30 Filed 2025-08-14
Unchanged Shares 0.0% 13F value change $0
13F 2025-09-30 Filed 2025-11-14
Unchanged Shares 0.0% 13F value change $0
13F 2025-12-31 Filed 2026-02-17
Unchanged Shares 0.0% 13F value change $0
13F 2026-03-31 Filed 2026-05-15
Unchanged Shares 0.0% 13F value change $0
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 3,829,608 Last 4 periods +0 (0.0%) Total shares 3,829,608 Value $472.0M
Sessa Capital 4 filing periods
13F 2025-06-30 Filed 2025-08-13
New Shares - 13F value change +$450.6M
13F 2025-09-30 Filed 2025-11-14
Minor reduction Shares -0.8% 13F value change -$5.5M
13F 2025-12-31 Filed 2026-02-17
Major reduction Shares -27.4% 13F value change +$1.4M
13F 2026-03-31 Filed 2026-05-15
Minor reduction Shares -3.8% 13F value change -$42.7M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 0 Last 4 periods +3,275,849 (New) Total shares 3,275,849 Value $403.8M
Baillie Gifford legacy James Anderson 4 filing periods
13F 2025-06-30 Filed 2025-08-06
Major reduction Shares -42.2% 13F value change -$72.8M
13F 2025-09-30 Filed 2025-10-31
Minor reduction Shares -3.1% 13F value change -$5.9M
13F 2025-12-31 Filed 2026-01-23
Minor reduction Shares -3.6% 13F value change +$53.2M
13F 2026-03-31 Filed 2026-05-08
Minor reduction Shares -5.6% 13F value change -$24.2M
Settlement As of 13F 2026-03-31 · Filed 2026-05-08
Base shares 3,010,792 Last 4 periods -1,475,686 (-49.0%) Total shares 1,535,106 Value $189.2M
Glenview Capital Management Larry Robbins 2 filing periods
13F 2025-09-30 Filed 2025-11-14
New Shares - 13F value change +$9.7M
13F 2025-12-31 Filed 2026-02-17
Sold out Shares -100.0% 13F value change -$9.7M
Settlement As of 13F 2025-12-31 · Filed 2026-02-17
Base shares 0 Last 4 periods +0 (New) Total shares 0 Value $0
Duquesne Family Office Stanley Druckenmiller 2 filing periods
13F 2025-06-30 Filed 2025-08-15
New Shares - 13F value change +$28,682
13F 2025-09-30 Filed 2025-11-14
Sold out Shares -100.0% 13F value change -$28,682
Settlement As of 13F 2025-09-30 · Filed 2025-11-14
Base shares 0 Last 4 periods +0 (New) Total shares 0 Value $0
Icahn Enterprises / Icahn Capital Carl Icahn 2 filing periods
13F 2025-03-31 Filed 2025-05-15
New Shares - 13F value change +$17.5M
13F 2025-06-30 Filed 2025-08-14
Sold out Shares -100.0% 13F value change -$17.5M
Settlement As of 13F 2025-06-30 · Filed 2025-08-14
Base shares 0 Last 4 periods +0 (New) Total shares 0 Value $0

Recent mentions

No public mentions.